Progress towards therapies for disease modification in Parkinson's disease

The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifyi...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2021-07, Vol.20 (7), p.559-572
Main Authors: Vijiaratnam, Nirosen, Simuni, Tanya, Bandmann, Oliver, Morris, Huw R, Foltynie, Thomas
Format: Article
Language:English
Subjects:
Clinical trials
Failure
Intervention
Medical treatment
Movement disorders
Neurodegeneration
Neurodegenerative diseases
Parkinson's disease
Pathogenesis
Patients
Precision medicine
Quality of life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c535t-9e6e5efaf61d03a19b2d76ac35a55d14a45f2f9c55c6099aa2ed56d7e5544db63
cites cdi_FETCH-LOGICAL-c535t-9e6e5efaf61d03a19b2d76ac35a55d14a45f2f9c55c6099aa2ed56d7e5544db63
container_end_page 572
container_issue 7
container_start_page 559
container_title Lancet neurology
container_volume 20
creator Vijiaratnam, Nirosen
Simuni, Tanya
Bandmann, Oliver
Morris, Huw R
Foltynie, Thomas
description The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifying treatments might relate not only to inadequate approaches for the selection of therapeutic candidates but also to insufficient attention to detail in clinical trial design. Better understanding of Parkinson's disease pathogenesis associated with advances in laboratory models, the use of objective biomarkers of disease progression and target engagement, and a focus on agents known to be safe for human use, alongside the use of precision medicine approaches, should together greatly increase the likelihood for successful identification of disease-modifying treatments for Parkinson's disease.
doi_str_mv 10.1016/S1474-4422(21)00061-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2543444117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1474442221000612</els_id><sourcerecordid>2543444117</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-9e6e5efaf61d03a19b2d76ac35a55d14a45f2f9c55c6099aa2ed56d7e5544db63</originalsourceid><addsrcrecordid>eNqFkE9LAzEQxYMoWKsfQVjwYD2sJtkk655Ein8pWFDPIU0mmtpuamar-O3dbasHL57eMPzeY-YRcsjoKaNMnT0yUYpcCM4HnJ1QShXL-RbpbdZKbv_OnO-SPcQppZyJc9Yj9-MUXxIgZk38NMm1-grJLAJg5mPKXEAwCNk8uuCDNU2IdRbqbGzSW6gx1sf4w-yTHW9mCAcb7ZPn66un4W0-eri5G16OcisL2eQVKJDgjVfM0cKwasJdqYwtpJHSMWGE9NxXVkqraFUZw8FJ5UqQUgg3UUWfDNa5ixTfl4CNnge0MJuZGuISNZeiEEIwVrbo0R90Gpepbq_rqBaoWNlRck3ZFBETeL1IYW7Sl2ZUdw3rVcO6q09zplcNa976LtY-aL_9CJA02gC1BRcS2Ea7GP5J-AavAYKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2541739177</pqid></control><display><type>article</type><title>Progress towards therapies for disease modification in Parkinson's disease</title><source>Elsevier</source><creator>Vijiaratnam, Nirosen ; Simuni, Tanya ; Bandmann, Oliver ; Morris, Huw R ; Foltynie, Thomas</creator><creatorcontrib>Vijiaratnam, Nirosen ; Simuni, Tanya ; Bandmann, Oliver ; Morris, Huw R ; Foltynie, Thomas</creatorcontrib><description>The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifying treatments might relate not only to inadequate approaches for the selection of therapeutic candidates but also to insufficient attention to detail in clinical trial design. Better understanding of Parkinson's disease pathogenesis associated with advances in laboratory models, the use of objective biomarkers of disease progression and target engagement, and a focus on agents known to be safe for human use, alongside the use of precision medicine approaches, should together greatly increase the likelihood for successful identification of disease-modifying treatments for Parkinson's disease.</description><identifier>ISSN: 1474-4422</identifier><identifier>EISSN: 1474-4465</identifier><identifier>DOI: 10.1016/S1474-4422(21)00061-2</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Clinical trials ; Failure ; Intervention ; Medical treatment ; Movement disorders ; Neurodegeneration ; Neurodegenerative diseases ; Parkinson's disease ; Pathogenesis ; Patients ; Precision medicine ; Quality of life</subject><ispartof>Lancet neurology, 2021-07, Vol.20 (7), p.559-572</ispartof><rights>2021 Elsevier Ltd</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-9e6e5efaf61d03a19b2d76ac35a55d14a45f2f9c55c6099aa2ed56d7e5544db63</citedby><cites>FETCH-LOGICAL-c535t-9e6e5efaf61d03a19b2d76ac35a55d14a45f2f9c55c6099aa2ed56d7e5544db63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Vijiaratnam, Nirosen</creatorcontrib><creatorcontrib>Simuni, Tanya</creatorcontrib><creatorcontrib>Bandmann, Oliver</creatorcontrib><creatorcontrib>Morris, Huw R</creatorcontrib><creatorcontrib>Foltynie, Thomas</creatorcontrib><title>Progress towards therapies for disease modification in Parkinson's disease</title><title>Lancet neurology</title><description>The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifying treatments might relate not only to inadequate approaches for the selection of therapeutic candidates but also to insufficient attention to detail in clinical trial design. Better understanding of Parkinson's disease pathogenesis associated with advances in laboratory models, the use of objective biomarkers of disease progression and target engagement, and a focus on agents known to be safe for human use, alongside the use of precision medicine approaches, should together greatly increase the likelihood for successful identification of disease-modifying treatments for Parkinson's disease.</description><subject>Clinical trials</subject><subject>Failure</subject><subject>Intervention</subject><subject>Medical treatment</subject><subject>Movement disorders</subject><subject>Neurodegeneration</subject><subject>Neurodegenerative diseases</subject><subject>Parkinson's disease</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Quality of life</subject><issn>1474-4422</issn><issn>1474-4465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkE9LAzEQxYMoWKsfQVjwYD2sJtkk655Ein8pWFDPIU0mmtpuamar-O3dbasHL57eMPzeY-YRcsjoKaNMnT0yUYpcCM4HnJ1QShXL-RbpbdZKbv_OnO-SPcQppZyJc9Yj9-MUXxIgZk38NMm1-grJLAJg5mPKXEAwCNk8uuCDNU2IdRbqbGzSW6gx1sf4w-yTHW9mCAcb7ZPn66un4W0-eri5G16OcisL2eQVKJDgjVfM0cKwasJdqYwtpJHSMWGE9NxXVkqraFUZw8FJ5UqQUgg3UUWfDNa5ixTfl4CNnge0MJuZGuISNZeiEEIwVrbo0R90Gpepbq_rqBaoWNlRck3ZFBETeL1IYW7Sl2ZUdw3rVcO6q09zplcNa976LtY-aL_9CJA02gC1BRcS2Ea7GP5J-AavAYKQ</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Vijiaratnam, Nirosen</creator><creator>Simuni, Tanya</creator><creator>Bandmann, Oliver</creator><creator>Morris, Huw R</creator><creator>Foltynie, Thomas</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>202107</creationdate><title>Progress towards therapies for disease modification in Parkinson's disease</title><author>Vijiaratnam, Nirosen ; Simuni, Tanya ; Bandmann, Oliver ; Morris, Huw R ; Foltynie, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-9e6e5efaf61d03a19b2d76ac35a55d14a45f2f9c55c6099aa2ed56d7e5544db63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical trials</topic><topic>Failure</topic><topic>Intervention</topic><topic>Medical treatment</topic><topic>Movement disorders</topic><topic>Neurodegeneration</topic><topic>Neurodegenerative diseases</topic><topic>Parkinson's disease</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vijiaratnam, Nirosen</creatorcontrib><creatorcontrib>Simuni, Tanya</creatorcontrib><creatorcontrib>Bandmann, Oliver</creatorcontrib><creatorcontrib>Morris, Huw R</creatorcontrib><creatorcontrib>Foltynie, Thomas</creatorcontrib><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Psychology Journals</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Lancet neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vijiaratnam, Nirosen</au><au>Simuni, Tanya</au><au>Bandmann, Oliver</au><au>Morris, Huw R</au><au>Foltynie, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progress towards therapies for disease modification in Parkinson's disease</atitle><jtitle>Lancet neurology</jtitle><date>2021-07</date><risdate>2021</risdate><volume>20</volume><issue>7</issue><spage>559</spage><epage>572</epage><pages>559-572</pages><issn>1474-4422</issn><eissn>1474-4465</eissn><abstract>The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifying treatments might relate not only to inadequate approaches for the selection of therapeutic candidates but also to insufficient attention to detail in clinical trial design. Better understanding of Parkinson's disease pathogenesis associated with advances in laboratory models, the use of objective biomarkers of disease progression and target engagement, and a focus on agents known to be safe for human use, alongside the use of precision medicine approaches, should together greatly increase the likelihood for successful identification of disease-modifying treatments for Parkinson's disease.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S1474-4422(21)00061-2</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1474-4422
ispartof Lancet neurology, 2021-07, Vol.20 (7), p.559-572
issn 1474-4422
1474-4465
language eng
recordid cdi_proquest_miscellaneous_2543444117
source Elsevier
subjects Clinical trials
Failure
Intervention
Medical treatment
Movement disorders
Neurodegeneration
Neurodegenerative diseases
Parkinson's disease
Pathogenesis
Patients
Precision medicine
Quality of life
title Progress towards therapies for disease modification in Parkinson's disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T09%3A55%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progress%20towards%20therapies%20for%20disease%20modification%20in%20Parkinson's%20disease&rft.jtitle=Lancet%20neurology&rft.au=Vijiaratnam,%20Nirosen&rft.date=2021-07&rft.volume=20&rft.issue=7&rft.spage=559&rft.epage=572&rft.pages=559-572&rft.issn=1474-4422&rft.eissn=1474-4465&rft_id=info:doi/10.1016/S1474-4422(21)00061-2&rft_dat=%3Cproquest_cross%3E2543444117%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c535t-9e6e5efaf61d03a19b2d76ac35a55d14a45f2f9c55c6099aa2ed56d7e5544db63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2541739177&rft_id=info:pmid/&rfr_iscdi=true